High cholesterol and lipid metabolism disorder: causes, risk & modern treatment

At a glance

FrequencyElevated LDL cholesterol affects a large proportion of adults in Germany — many are unaware of it
Why it mattersElevated LDL cholesterol is one of the most important risk factors for heart attack and stroke
Key valueLDL cholesterol (low-density lipoprotein) — the lower, the better for the cardiovascular risk
TreatmentLifestyle change + statins as first-line therapy, if needed ezetimibe, bempedoic acid, PCSK9 inhibitors
GuidelineESC/EAS 2025 Focused Update on dyslipidaemia
ICD-10E78 (disorders of lipoprotein metabolism)

1. What is high cholesterol?

Cholesterol is a vital component of every body cell. The body produces most of it itself; some is taken in through food. It becomes a problem when LDL cholesterol (colloquially: bad cholesterol) is permanently elevated — because LDL deposits in the vessel walls and promotes atherosclerosis (vascular calcification).¹

Elevated LDL cholesterol is one of the most important modifiable risk factors for heart attack, stroke and other cardiovascular diseases. The evidence for this is clear according to current knowledge: the lower the LDL cholesterol, the lower the risk — the ESC/EAS guideline (Focused Update 2025) frames it as a basic principle.¹

Very treatable — even without symptoms High cholesterol can usually be treated well — through a combination of lifestyle change and medications. Because the condition causes no symptoms for a long time, regular monitoring of the values is especially important.

2. LDL, HDL, triglycerides — what do the values mean?

  • LDL cholesterol: transports cholesterol into the vessels and deposits it there. Elevated values promote atherosclerosis. The most important target value of treatment.¹
  • HDL cholesterol: transports excess cholesterol back to the liver (a protective function). Low values are considered a risk factor. According to current knowledge, however, there is no medication that lowers the cardiovascular risk by raising HDL.
  • Triglycerides: blood fats that rise with excess energy intake (especially sugar, alcohol, excess weight). Strongly elevated triglycerides can increase the cardiovascular risk and in rare cases trigger an acute pancreatitis.
  • Total cholesterol: the sum of LDL, HDL and VLDL. Often measured, but less informative than LDL cholesterol alone.
  • Lipoprotein(a) (Lp(a)): a genetically determined risk factor that was included as a risk modifier in the ESC/EAS update 2025. It is usually measured once in a lifetime. It can currently barely be influenced by medication — new therapies are in development.

3. Causes and risk factors

  • Diet: a high proportion of saturated fatty acids (fatty meat, sausage, cheese, butter, coconut fat) and trans fatty acids (fried food, baked goods, ready-made products) can raise LDL.
  • Lack of exercise: a sedentary lifestyle.
  • Excess weight: obesity usually raises LDL and triglycerides and lowers HDL.
  • Genetics: familial hypercholesterolaemia (FH) is a common genetic condition that leads to strongly elevated LDL values already at a young age. It is often not recognized (see the separate section below).
  • Other conditions: hypothyroidism, chronic kidney disease, type 2 diabetes, liver diseases.
  • Medications: certain medications can affect lipid metabolism (e.g. cortisone, beta blockers, thiazides, immunosuppressants).

4. Symptoms

High cholesterol usually causes no symptoms That is why it is often only discovered when a cardiovascular disease has already occurred (heart attack, stroke, peripheral arterial disease). Regular blood tests are therefore important — especially with risk factors or a positive family history.¹

With very strongly elevated values (especially with familial hypercholesterolaemia), visible signs can appear:

  • Xanthomas: cholesterol deposits in tendons or under the skin
  • Xanthelasmas: yellowish deposits on the eyelids
  • Arcus lipoides: a whitish ring around the cornea

These signs are rare but diagnostically telling — they should prompt consideration of a familial form.


5. Diagnosis and risk assessment

  • Lipid profile: total cholesterol, LDL, HDL, triglycerides — usually fasting or non-fasting (the results are comparable for most values). LDL is the decisive target value.
  • Risk assessment: the ESC/EAS guideline recommends an individual risk assessment — in the 2025 update with SCORE2 (for ages 40–69) and SCORE2-OP (for ages 70–89). The overall risk determines the LDL target values and the treatment intensity.¹
  • LDL target values (ESC/EAS 2025): depend on the individual cardiovascular risk. The higher the risk, the lower the target value. For people with existing cardiovascular disease or a very high risk, the lowest target values usually apply.¹
  • Lipoprotein(a): recommended as a risk modifier in the 2025 update — it should usually be measured once in a lifetime.

More: Preparing for a doctor's appointment, Understanding your blood values.

6. Treatment: lifestyle

Lifestyle changes are the basis of every cholesterol treatment — regardless of whether medications are used.¹

  • Reduce saturated fatty acids — less fatty meat, sausage, cheese, butter, coconut fat; instead unsaturated fatty acids (olive oil, nuts, avocado, oily fish)
  • Avoid trans fatty acids — fried food, industrial baked goods, ready-made products
  • Increase fibre — wholegrain products, vegetables, legumes, fruit
  • Normalize weight with excess weight
  • Regular exercise — can lower LDL and raise HDL
  • Stopping smoking — smoking damages the blood vessels independently of cholesterol
  • Reduce alcohol — can lower triglycerides

7. Treatment: medications

When lifestyle changes alone are not enough to reach the individual LDL target values, medications are used. The decision depends on the overall risk.¹

First line Statins

Statins are the best-studied and most frequently used cholesterol-lowering drugs. They inhibit the body's own cholesterol production in the liver and can considerably lower LDL cholesterol. Statins demonstrably reduce the risk of heart attack, stroke and cardiovascular death.¹

  • Usually taken once a day (mostly in the evening)
  • Common side effects: muscle complaints (mostly mild and temporary); rarely severe muscle damage
  • Liver values can rise slightly — usually checked at the start
  • Many people tolerate statins well — a relevant proportion of the reported intolerances is, according to studies, not caused by the medication (the nocebo effect)
Combination Ezetimibe
Ezetimibe
Inhibits the absorption of cholesterol in the bowel. Often combined with statins when the statin alone is not enough. Can also be used as a monotherapy when statins are not tolerated.
New in 2025 Bempedoic acid
Bempedoic acid
New in the ESC/EAS guideline 2025. An oral agent that, like statins, inhibits cholesterol production but has a different mechanism of action. Recommended with statin intolerance or as a supplement to statins.¹
Escalation PCSK9 inhibitors
Evolocumab, alirocumab
Very effective LDL-lowering drugs that are administered as an injection. Usually used when statins + ezetimibe + bempedoic acid are not enough or are not tolerated. Reimbursement by the statutory health insurance (in Germany GKV) is tied to certain conditions.
Triglycerides Fibrates
Fibrates
Used with strongly elevated triglycerides.
Statins: the benefit usually clearly outweighs Statins are among the best-studied medications of all. In people with an elevated cardiovascular risk, the benefit usually clearly outweighs the risks. Statins should not be stopped on your own — if a side effect is suspected, talk to the treating practice. More: Stopping medications.

8. Familial hypercholesterolaemia

Familial hypercholesterolaemia (FH) is a common genetic condition that leads to strongly elevated LDL values — already at a young age and independently of lifestyle. The heterozygous form affects, by estimates, about one in several hundred people but is usually considerably underdiagnosed.¹

  • Suspected with clearly elevated LDL (especially at a younger age), a positive family history (heart attack or stroke in relatives before the age of 55 (men) or 60 (women)), xanthomas
  • Diagnosis: clinical scoring systems (e.g. the Dutch Lipid Clinic Network Score) and/or genetic testing
  • Treatment: early and consistent LDL lowering (statins + ezetimibe, if needed PCSK9 inhibitors); lifestyle change alone is usually not enough with FH
  • Cascade screening: first-degree relatives should also be tested

How brite helps you with high cholesterol

A statin in the evening, ezetimibe with it, a new LDL result every three months and the question of whether the target has been reached — plus high blood pressure and diabetes in the background. Cholesterol treatment is often part of a larger cardiovascular plan. brite keeps it clear.

  • Medication reminder — a statin in the evening, ezetimibe or bempedoic acid in the morning: brite reminds you on time. Precisely because statins are taken for life, a routine helps. Set up a reminder
  • Interaction check — a statin plus grapefruit juice? Plus macrolide antibiotics? Plus certain antifungals? brite shows when statin levels can rise unintentionally — and with them the risk of muscle side effects. Check now
  • Health history — document LDL, HDL, triglycerides and total cholesterol over time. That way you can clearly see whether the treatment reaches the LDL target — or whether an escalation would make sense. Track your history
  • Digital medication plan — all your medications clearly laid out for cardiology, your family doctor and the lipid clinic. Helps especially when, alongside the statin, blood pressure lowering drugs and antidiabetics are added. Go to medication plan
Get started for free
brite App

FAQ: Common questions about high cholesterol

LDL cholesterol. It is the central target value of treatment and the most important modifiable risk factor for heart attack and stroke. The target value depends on the individual cardiovascular risk.¹
Usually yes — when there is a clear indication (an elevated cardiovascular risk or existing cardiovascular disease). Cholesterol usually rises again after stopping, and the protective effect is lost. Statins should not be stopped on your own.
Muscle complaints are the most commonly reported side effect but occur in a mild form in most people and are often temporary. Studies show that a relevant part of the muscle complaints under statins is not caused by the medication (the nocebo effect). If suspected, address the treating practice — there are often alternatives.
A new oral cholesterol-lowering drug that was included in the ESC/EAS guideline in 2025. It inhibits cholesterol production through a different mechanism than statins. Recommended with statin intolerance or as a supplement when the LDL target is not reached.¹
A common genetic condition with strongly elevated LDL from a young age. It is often not recognized. Affected people have a clearly elevated risk of early heart attacks. Early diagnosis and consistent treatment are crucial. First-degree relatives should also be tested.¹
Lifestyle changes (diet, exercise, weight) can usually lower LDL moderately. With a higher risk or strongly elevated values, they are usually not enough — then medications (especially statins) are recommended. With familial hypercholesterolaemia, diet alone is not enough.
For most clinical decisions, a non-fasting lipid profile is sufficient. Fasting values can be more precise with strongly elevated triglycerides. The treating practice usually gives guidance.
A genetically determined risk factor for cardiovascular disease that was included as a risk modifier in the ESC/EAS update 2025. It should usually be measured once in a lifetime. It can currently barely be influenced by medication — new therapies are in development.¹

11. Related topics

Sources

  1. ESC/EAS 2025 Focused Update der Dyslipidämie-Leitlinie (auf Basis der 2019er Leitlinie). eurheartj (Oxford Academic)
  2. gesundheitsinformation.de (IQWiG): Erhöhte Cholesterinwerte. gesundheitsinformation.de
  3. DGK-Kommentar zum ESC/EAS-Update 2025 (Die Kardiologie 2026). Springer
  4. Deutsche Gesellschaft zur Bekämpfung von Fettstoffwechselstörungen und ihren Folgeerkrankungen (DGFF, Lipid-Liga). lipid-liga.de
Medical disclaimer: This article is for general information and does not replace medical advice, diagnosis or treatment. LDL target values and treatment intensity depend on the individual cardiovascular risk and are determined by the treating practice. Statins and other lipid-lowering drugs should not be stopped on your own. Last updated: April 2026.